Rasmussen’s Encephalitis Market

Market Qverview:

The Rasmussen’s encephalitis market reached a value of USD 389.7 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 632.4 Million by ​2035​, exhibiting a growth rate (CAGR) of 4.50% during ​2025-2035​.

The Rasmussen’s encephalitis market has been comprehensively analyzed in IMARC's new report titled "Rasmussen’s Encephalitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Rasmussen's encephalitis is a rare illness characterized by chronic inflammation (encephalitis) of one hemisphere of the brain. As a result, the patient generally experiences repeated episodes of uncontrolled electrical disruptions in the brain, which result in epileptic seizures (epilepsy) and gradual cerebral damage. This induces loss of function in the affected brain hemisphere. As the inflammation progresses, it causes worsening weakness in one side of the body and mental decline. Other features may include loss of vision for one side of the visual field (hemianopia) and cognitive difficulties affecting learning, memory, or language. The diagnostic evaluation of this condition is based on a comprehensive medical history, as well as physical and neurological examination. The healthcare professional might also recommend a complete blood count (CBC) to provide information about infection and unusual electrolyte levels, such as magnesium, potassium, and calcium. Furthermore, magnetic resonance imaging (MRI) and computed tomography (CT) scans may be performed to indicate scar tissue, tumors, or structural problems in the brain.

The escalating prevalence of autoimmune disorder, where the body's immune system mistakenly attacks healthy brain tissue in one hemisphere of the brain, causing inflammation and neurological damage, is primarily driving the Rasmussen’s encephalitis market. In addition to this, the inflating utilization of intravenous immunoglobulins (IVIG), since it helps to modulate the immune system, reduce inflammation in the brain, and potentially slow down the progression of the disease, is also creating a positive outlook for the market. Moreover, the widespread adoption of anticonvulsant medication on account of its numerous advantages, like reduced neurological decline, improved overall well-being, and minimized hospitalizations, is further bolstering the market growth. Apart from this, the rising usage of hemispherectomy, in which the affected hemisphere is disconnected from the healthy side of the brain through strategic cuts, rather than completely removing large amounts of brain tissue is acting as another significant growth-inducing factor. Additionally, the emerging popularity of monoclonal antibodies that target CD20 proteins on B cells, depleting them to reduce the autoimmune attack on the brain, is expected to drive the Rasmussen’s encephalitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Rasmussen’s encephalitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Rasmussen’s encephalitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Rasmussen’s encephalitis market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Rasmussen’s encephalitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Rasmussen’s encephalitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Rasmussen’s encephalitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Rasmussen’s encephalitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Rasmussen’s encephalitis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Rasmussen’s encephalitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of Rasmussen’s encephalitis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Rasmussen’s encephalitis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Rasmussen’s encephalitis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with Rasmussen’s encephalitis across the seven major markets?
• What is the size of the Rasmussen’s encephalitis patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of Rasmussen’s encephalitis?
• What will be the growth rate of patients across the seven major markets?

Rasmussen’s Encephalitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Rasmussen’s encephalitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Rasmussen’s encephalitis market?
• What are the key regulatory events related to the Rasmussen’s encephalitis market?
• What is the structure of clinical trial landscape by status related to the Rasmussen’s encephalitis market?
• What is the structure of clinical trial landscape by phase related to the Rasmussen’s encephalitis market?
• What is the structure of clinical trial landscape by route of administration related to the Rasmussen’s encephalitis market?